Futura Medical shares rise on ED licensing deal with Haleon
Futura Medical
34.87p
08:09 15/11/24
0.00%
0.00p
Shares in Futura Medical gained on Monday after the company said it signed a licensing deal with consumer heath care giant Haleon for the rights to exclusively commercialise its topical, gel-based erectile dysfunction treatment MED3000 in the USA.
FTSE 100
8,044.51
08:35 15/11/24
n/a
n/a
FTSE 350
4,444.55
08:35 15/11/24
n/a
n/a
FTSE AIM All-Share
728.46
08:35 15/11/24
n/a
n/a
FTSE All-Share
4,403.01
08:35 15/11/24
n/a
n/a
Haleon
362.30p
08:35 15/11/24
0.08%
0.30p
Pharmaceuticals & Biotechnology
19,303.24
08:35 15/11/24
-2.48%
-491.72
Futura will receive an initial upfront payment of $4m, royalty payments on all sales of MED3000 by Haleon and potential commercial and performance-driven sales milestone payments totalling between $5m and $45m payable over the course of several years